Abbott said at CES that it will enter the consumer biowearables market – Bestgamingpro

Spread the love


Abbott, a US medical equipment company, is branching out into consumer biosensing wearables.

Abbott’s chairman and CEO, Robert B Ford, stated in a health tech keynote at CES yesterday that the company is creating a new line of consumer biowearables – named Lingo — for more general fitness and wellness purposes.

During his keynote, he added, “Technology provides us the capacity to digitize, decentralize, and democratize healthcare, create a shared language between you and your doctor — and put more control of your health in your hands.” “We’re building a future where you and your loved ones will receive more personalized and accurate care. It’s taking place right now. And its potential is nothing short of amazing.”

The Lingo sensing technology is being developed to measure “key signals” in the body, such as glucose, ketones, and lactate, according to Ford, who added that it may be used to track alcohol levels in the future.

Last year, the business released the Libre Sense Glucose Sport Biowearableiii, a biosensor built for athletes that were made available in Europe and have been utilized by athletes such as marathon world record holder Eliud Kipchoge to support their training needs.

Abbott’s goal with Lingo is to make glucose monitoring more accessible to people who want to lose weight, sleep better, have more energy, and think more clearly.

It claimed it is developing the biosensor to assess other biomarkers besides glucose to enable this extended usage.

In a news release, the business started, “A ketone biowearable is being created to detect ketones continually, observe how fast you are entering into ketosis, and understand exactly what maintains you there by providing insights on dieting and weight reduction.” “A lactate biowearable is being developed to track continuous lactate buildup during exercise, which can be utilized as a performance indicator.”

In recent years, a slew of startups in the United States, Europe, and Asia have attempted to commercialize CGM hardware — including Abbott’s existing sensors — for a variety of non-medical uses, launching real-time blood glucose tracking services aimed at fitness enthusiasts, dieters, and other health-conscious consumers.

Abbott’s fast entry into the market implies it sees a lot of potentials for biosensing consumer devices to become ubiquitous.

Leave a Reply

Your email address will not be published. Required fields are marked *